ArticleFrontiers in cell and developmental biology2026
Valproic acid sensitizes resveratrol to induce glioma cell apoptosis via the ROS-PDCD4-Bax signaling axis.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma is an aggressive malignant brain tumor with poor prognosis. Resveratrol (RES) possesses anti-tumor activity yet limited clinical value. Valproic acid (VPA), a histone deacetylase inhibitor, boosts multiple anti-cancer drugs' efficacy. This study explored RES/VPA synergy in glioma cell lines and syngeneic mouse tumors, and confirmed the reactive oxygen species (ROS)-programmed cell death protein 4 (PDCD4)-Bax cascade drives combined pro-apoptotic and anti-invasive effects. Methods: CCK-8 detected cell proliferation; morphology and AO/EB staining assessed apoptosis. Wound healing and transwell assays measured migration. Western blot analyzed apoptosis and migration-related proteins, including PDCD4. Dihydroethidium staining tested intracellular ROS. Rescue assays used N-acetylcysteine (NAC) and PDCD4 knockdown; subcutaneous syngeneic mice validated Results: VPA alone exerted no significant cytotoxicity on glioma cells (p > 0.05 vs. NC), while RES inhibited U87MG and U251 cell proliferation in a concentration-dependent manner (p < 0.05, p < 0.01 vs. NC). RES/VPA co-treatment significantly enhanced cytotoxicity, suppressed migration and induced glioma cell apoptosis, with anti-tumor efficacy comparable to clinical doxorubicin (p > 0.05 Com vs. DOX; p < 0.01 Com vs. RES). Mechanistically, the combination markedly increased intracellular ROS accumulation (p < 0.001 Com vs. RES), upregulated PDCD4 expression (p < 0.01 Com vs. RES), and modulated apoptosis- and EMT-related protein levels to trigger cell apoptosis. NAC-mediated ROS scavenging or PDCD4 knockdown significantly abolished the synergistic pro-apoptotic effect of the combination therapy (p < 0.01 vs. Com), verifying the critical ROS-PDCD4 signaling function. Conclusion: RES combined with VPA exerts synergistic anti-glioma effects via the ROS-PDCD4-Bax signaling pathway, providing experimental evidence for VPA as an adjuvant in RES-based therapy. This combinatorial strategy overcomes the insufficient anti-tumor potency of RES monotherapy at the cellular and murine tumor level, expands the preclinical antitumor research value of natural polyphenols, and provides laboratory experimental reference for subsequent translational exploration of glioma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.